Fax: (919) 684-8794
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer†
Article first published online: 29 MAY 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 15, pages 3376–3378, 1 August 2009
How to Cite
Moul, J. W. (2009), Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer, 115: 3376–3378. doi: 10.1002/cncr.24393
See referenced original article on pages 3437-45, this issue.
- Issue published online: 20 JUL 2009
- Article first published online: 29 MAY 2009
- Manuscript Accepted: 12 JAN 2009
- Manuscript Received: 5 JAN 2009
The current issue of Cancer includes a report on a concise, randomized controlled trial (RCT) with long-term follow-up that favors combined androgen blockade with bicalutamide versus lutenizing hormone-releasing hormone monotherapy in Japanese men with locally advanced and metastatic prostate cancer. It has been 20 years since the first RCT on CAB was published, and the debate continues.